2024 - Discovering Functional & Developable Bispecific Antibodies Using Fully Human Common Light Chain Transgenic Mice

Discover a groundbreaking webinar exploring innovative approaches in the discovery of bispecific antibodies using the ATX-CLC mouse strain along with reviewing case studies and validated data. Bispecific antibodies continue to be a transformative approach to treating a wide range of diseases across a range of mechanisms including T-Cell engagers, biparatopics, cis-targeting and more. However, discovering novel, developable and therapeutically relevant bispecifics is technically and strategically challenging and requires deep domain expertise as well as next-generation, integrated workflows. Alloy Therapeutic’s bispecific discovery services integrate best-in-class discovery platform technologies with world-class scientific experts to serve as an extension of research and development (R&D) teams and take bispecific programs further faster.
Read more...
A number of case studies from recent campaigns will also be discussed, where the ATX-CLC platform and fully integrated bispecific antibody discovery workflow were utilized. One such campaign is where a number of binders with high specificity and affinity for Claudin 18.2 (CLDN18.2), a very challenging target with high-homology family members, were discovered. In another case, the team discovered programmed cell death-1 cluster of differentiation 28 (PD-1 X CD28) bispecifics that promoted the proliferation of exhausted clusters of differentiation 4 (CD4+) T cells and demonstrated excellent developability profiles.
Join this webinar to learn more about bispecific antibodies development and how ATX-CLC mouse strain can help enable the discovery of novel bispecific therapeutic concepts.
Keywords: Antibody, Drug Discovery, Mouse Model, Proteomics, Animal Models, Protein Engineering, Therapeutic Antibody Development, Bispecific Antibody